Fredun Pharmaceuticals Share Price

Fredun Pharmaceuticals Investment Rating

• Master Rating:

• Fredun Pharmaceuticals has an operating revenue of Rs. 239.54 Cr. on a trailing 12-month basis. An annual revenue growth of 67% is outstanding, Pre-tax margin of 4% needs improvement, ROE of 9% is fair but needs improvement. The company has a debt to equity of 62%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 30% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 123 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has great fundamentals and technical strength to stay in momentum.